GLP-1 medications have transformed the way clinicians treat obesity and metabolic disease. Prescription drugs such as semaglutide and tirzepatide (a dual GLP-1 and GIP receptor agonist) can produce significant weight loss while improving blood sugar control and reducing cardiovascular risk.
But it’s important to understand that losing weight and optimizing health aren’t necessarily synonymous.
When someone tells me they’ve lost 30 pounds on a GLP-1, the number on the scale doesn’t tell me much about their metabolic health. I also want to know: How much of that weight came from fat versus muscle? Has your visceral fat decreased? What happened to insulin sensitivity, blood pressure, and ApoB? Are you stronger and more physically fit? Are you consuming enough protein and essential nutrients? Are the habits you’ve developed sustainable over the long term?
These questions matter because GLP-1-associated muscle loss can occur alongside fat loss. While losing some lean mass is expected during any weight loss journey, preserving muscle during GLP-1 treatment is important, particularly so as you age.
GLP-1s can be powerful tools for improving overall health. But they are not the end-all, be-all. They should be viewed as one component of a broader strategy designed to improve metabolic health, body composition, cardiovascular risk, fitness, and long-term function.
Are GLP-1s enough for long-term metabolic health?
GLP-1 receptor agonists mimic the effects of glucagon-like peptide-1, a naturally occurring hormone involved in blood sugar regulation, appetite, and digestion. Some newer medications target GLP-1 along with additional pathways. [1]
For some patients, these medications can lead to substantial weight loss and meaningful improvements in their cardiometabolic health. But medication alone doesn't address every factor that determines healthspan.
Current obesity pharmacotherapy guidance emphasizes that medication should be used alongside nutrition, physical activity, behavioral interventions, and ongoing clinical care. That combined approach matters because body weight is just one part of metabolic health.
For example, someone can reach a lower weight while still having elevated ApoB, insulin resistance, high blood pressure, poor cardiorespiratory fitness, excess visceral fat, low bone mass, nutritional deficiencies, or inadequate muscle mass.
This is why the endpoint of GLP-1 treatment shouldn’t simply be reaching a goal weight. The larger question is whether your treatment protocol is creating a healthier, stronger, and more metabolically resilient body.
Why weight loss doesn’t always indicate optimal health
The scale can be useful to a degree, but it can’t tell you what you’re losing.
When your body weight decreases, that change can come from several compartments, including body fat, lean tissue, and water. Think of it this way: two people can lose the same number of pounds while experiencing very different changes in body composition and metabolic health.
Ideally, you want your weight loss to reduce excess body fat, particularly visceral fat which is linked to various chronic diseases, while preserving as much metabolically and functionally important lean tissue as possible.
Visceral fat is the fat stored around internal organs. Higher levels are strongly associated with insulin resistance and cardiovascular and metabolic disease.
Muscle, on the other hand, is different. Skeletal muscle helps regulate your blood glucose (sugar) levels, supports strength and mobility, and contributes to energy expenditure (muscle burns more calories than fat), allowing you to maintain physical independence as we age.
This is why I encourage patients to think beyond “How much weight have I lost?” and start asking “What kind of weight have I lost, and what does that mean for my overall health?”
Does GLP-1 cause muscle loss?
GLP-1 medications can be associated with loss of lean mass. But again, whenever someone loses a meaningful amount of body weight, lean tissue may be lost along with fat. GLP-1 drugs like semaglutide don’t inherently or uniquely eat away at muscle mass.
The more useful clinical question is how much lean tissue someone is losing relative to fat and whether we, meaning you and your clinician, can minimize muscle loss through diet and exercise — specifically, resistance training.
This is especially critical for older adults. Worldwide, sarcopenia, or age-related loss of muscle mass, strength and physical function, affects 10-16% of elderly people. [2] But it also applies to anyone beginning treatment with relatively low muscle mass or losing substantial amounts of weight quickly.
Why lean mass matters during weight loss
Muscle isn’t just important for athletic performance. It’s metabolically active tissue that plays an important role in healthy aging.
Skeletal muscle helps remove glucose from the bloodstream and store it for later use, making it an important part of blood sugar regulation and metabolic health. It also supports strength, balance, and mobility, helping you continue doing everyday activities like walking, climbing stairs, or doing the dishes independently as you age.
Because people naturally lose muscle mass with age, preserving muscle becomes increasingly important for maintaining metabolic health and physical function later in life. If significant weight loss accelerates that decline, someone could theoretically become lighter without necessarily becoming stronger or more physically capable.
The goal should be to improve body composition by reducing excess fat while protecting the lean tissue that supports metabolic health and long-term function.
How body composition differs from body weight
A standard scale cannot distinguish between fat and lean tissue. That’s why we use DEXA scanning at Biograph to evaluate body composition in considerably greater detail. This allows us to measure fat mass and lean mass while also providing insight into your visceral fat and bone mass.
Rather than relying solely on body weight or BMI, we can assess measures such as fat-free mass index and appendicular lean mass, which provides information about lean tissue in your arms and legs.
That establishes a baseline before or during GLP-1 treatment and gives us something objective to track over time.
How to prevent muscle loss on GLP-1 medication
There’s no way to guarantee that someone will lose exclusively body fat during weight loss. But several strategies can help prioritize muscle preservation while taking a GLP-1. [3]
Prioritize protein and nutrient density
GLP-1 medications reduce appetite by quieting “food noise,” which is one reason they’re effective. But eating substantially less food can also make it harder to consume adequate protein, vitamins, minerals, and overall energy.
Protein is an essential macronutrient for everyone, but it becomes especially important while taking a GLP-1 because it supplies the amino acids needed to maintain and repair muscle tissue.
Rather than simply telling someone to eat more protein, however, it’s helpful to have a daily target based on your age, body composition, activity level, medical conditions, and overall energy needs. Meals should also remain nutrient-dense, providing adequate fiber, healthy fats, vitamins, minerals, and other essential nutrients despite smaller portions.
Strength train consistently
Resistance training is one of the best ways to retain and increase muscle mass at any age.
Strength training two or more times per week, when medically appropriate, can help preserve strength and lean tissue during weight loss.
Strength training should also be paired with regular aerobic activity. While resistance training helps protect muscle during weight loss, aerobic exercise supports cardiorespiratory fitness, another important marker of long-term health. This is why we measure VO2 max at Biograph.
Track body composition, not just scale weight
DEXA allows clinicians to track whether changes are occurring primarily in your fat mass or lean mass and whether or not your visceral fat content is improving. Regular measurements can then help identify whether your nutrition and exercise-based interventions are supporting your metabolic health.
Monitor bone health, fitness, and recovery
Rapid or substantial weight loss can also raise questions about bone health, nutritional adequacy, physical performance, and recovery, especially in older adults and people who begin treatment with existing risk factors such as low bone mass.
Bone masssity testing, VO2 max, strength assessments, sleep evaluation, and exercise performance can provide additional context into how your body is responding to treatment.
If the scale is moving in the desired direction but your strength, fitness, or bone health is deteriorating, that’s a major signal that your current strategy needs to be adjusted.
What should a metabolic health assessment include?
There’s no single metabolic health test that tells us everything we need to know. A comprehensive metabolic health assessment should combine multiple measurements to answer several different questions:
How is your body composition changing?
How effectively are you regulating blood sugar?
What is your cardiovascular risk?
How physically fit are you?
Are the interventions you’re using actually improving these measures over time?
Here’s a closer look at each of these factors.
Body composition
DEXA can measure your fat mass, lean mass, visceral fat, and bone mass. During GLP-1 treatment, metrics such as fat-free mass index and appendicular lean mass can be particularly useful for identifying whether clinically meaningful lean tissue is being preserved.
Blood sugar, insulin, and lipid markers
Weight loss frequently improves metabolic markers, but it’s important to screen for each of these to make sure your current treatment protocol is moving the needle on certain markers.
A comprehensive blood panel can evaluate fasting glucose, HbA1c, insulin-related measures, triglycerides, LDL cholesterol, and ApoB, among other biomarkers.
ApoB is particularly useful because it reflects the number of atherogenic lipoprotein particles circulating in the blood. Someone can lose significant weight and still have cardiovascular risk factors that require specialized attention.
Depending on your individual risk, other biomarkers such as lipoprotein(a), liver markers, and nutritional measures may provide your care team with additional context about your cardiometabolic health.
Cardiovascular risk and blood pressure
Obesity, insulin resistance, hypertension, and cardiovascular disease frequently overlap, which makes cardiovascular assessment an important part of metabolic care.
Traditional screenings such as blood pressure readings and advanced blood work provide part of that picture. For some people, cardiovascular imaging such as a coronary CT angiography (CCTA) or coronary artery calcium (CAC) scan may also be appropriate to determine whether risk factors have already translated into detectable arterial disease.
Fitness, sleep, and readiness for behavior change
How well you move, recover, and sleep can provide additional insight into your metabolic health.
VO2 max measures cardiorespiratory fitness, while strength and movement assessments can help evaluate physical capacity. Sleep evaluation can also identify barriers to metabolic improvement, including sleep apnea or sleep fragmentation.
Behavioral readiness matters, too. GLP-1 medications can change appetite and support weight loss, but they can’t build your exercise routine, improve your sleep, or determine the quality of your diet. Developing sustainable habits alongside treatment is what can help you turn weight loss into meaningful improvements in your metabolic health long-term. [4]
What happens if you stop taking a GLP-1?
Obesity is a chronic disease, and for many people, GLP-1 medication may require long-term treatment. Research and clinical guidance show that discontinuing obesity pharmacotherapy frequently results in weight regain and the recurrence or worsening of cardiometabolic risk factors. [4,5]
Adequate protein intake, resistance training, cardiovascular fitness, healthy sleep habits, and sustainable nutrition patterns during treatment create a stronger foundation for long-term health, whether medication is continued, adjusted, or eventually discontinued under physician supervision.
There are also clinical circumstances when a GLP-1 may need to be discontinued, including pregnancy. If you and your care team decide to stop treatment, having a plan for nutrition, exercise, weight management, and ongoing metabolic monitoring can help support your health through the transition.
At Biograph, we don’t evaluate GLP-1 success by the scale alone
DEXA body composition testing, comprehensive blood work, blood pressure, VO2 max testing, cardiovascular assessment, sleep evaluation, and personalized nutrition and exercise guidance can help determine whether weight loss is translating into better overall health.
By establishing a baseline and re-measuring over time, we can track changes in lean mass, visceral fat, metabolic markers, cardiovascular fitness, and other measures that matter for long-term health. These insights allow us to adjust the strategy as your health and treatment evolve.
The bottom line
GLP-1 medications can help you achieve substantial weight loss and meaningful improvements in cardiometabolic health. But they’re not the finish line.
Remember, the goal is to lose excess fat (especially visceral fat) while preserving muscle mass and your bone mass, improving metabolic and cardiovascular health, maintaining fitness, and building habits that support long-term health.
Commonly asked questions about GLP-1s and metabolic health
Do GLP-1s cause muscle loss?
Some lean mass can be lost during GLP-1-supported weight loss, just as it can during weight loss achieved through other methods. Adequate nutrition, sufficient protein, resistance training, and body composition monitoring can help prioritize muscle preservation.
How do you prevent muscle loss on Ozempic or semaglutide?
Strategies include consuming adequate protein and overall nutrition, resistance training consistently, and monitoring changes in body composition rather than relying solely on scale weight. Your unique health needs should be discussed with your healthcare team.
Can you be metabolically unhealthy after losing weight?
Yes. Lower body weight doesn't automatically mean every health marker is optimal. Insulin resistance, elevated ApoB or Lp(a), hypertension, poor cardiovascular fitness, visceral fat, low bone mass, and other risks may still warrant evaluation.
What labs should you track while taking a GLP-1?
Testing should be unique to you and your health history, but a metabolic health assessment may include fasting glucose, HbA1c, insulin-related markers, cholesterol, triglycerides, ApoB, liver markers, and other tests based on medical history and risk factors.
Should you strength train while taking a GLP-1?
For most people who can exercise safely, resistance training is an important part of maintaining and building muscle and strength during weight loss. Your exercise program should be appropriate for your current health, fitness, and physical capabilities.
What happens if you stop taking a GLP-1?
Weight regain and worsening of some cardiometabolic risk factors are common after GLP-1 medications are discontinued. Decisions about continuing or stopping treatment should be made with a clinician and accompanied by a long-term plan for nutrition, physical activity, and metabolic health monitoring.
Dr. Michael Doney is Biograph’s Executive Medical Director, with over 20 years of experience leading clinical care and advancing a more proactive, data-driven approach to medicine.
Clinical references
Wang X, Lin R, Sun Q, Xin X, Feng Q. GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies. Pharmacological Research. 2026;230:108331. doi:10.1016/j.phrs.2026.108331
Yuan S, Larsson SC. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism. 2023;144(155533):155533. doi:10.1016/j.metabol.2023.155533
Celletti F, Farrar J, De Regil L. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. Published online December 1, 2025. doi:10.1001/jama.2025.24288
Gudzune KA, Apovian CM, Aroda VR, et al. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. Diabetes Obesity and Cardiometabolic CARE. Published online January 13, 2026. doi:10.2337/doci25-0008
Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open. 2025;8(1):e2457349-e2457349. doi:10.1001/jamanetworkopen.2024.57349
